accacc2022acc2023acc2024acuteaddressingadherenceadjuvantadultsadvancedanalysisapproachesartarterialasco2021ashash2021ash2023ash2024asthmaatrialbasedbccbenefitsbetabetterbloodbreakingbreastcancercarcinomacardiologycardiovascularcarecellcervicalchallengeschangechemotherapychest2024cholesterolchronicclinicalcllcombinationcontrolcopdcoronarycovidcurrentcvdatadiabetesdiagnosisdiseasediseasesdrugsearlyeaseas2022easd2022effectefficacyehaeha2025ehra2022ers2024escesc2021esc2022esc2023esc2024eshesh2022esh2023esh2024esh2025esmoesmo2021esmo2023esmo2024eular2024eventsevidencefailurefibrillationfirstfocusfuturegallenglpguidanceguidelineshearther2hfpefhighhighlightshrhypertensionhypertensiveimmunotherapyimproveimprovesinhibitorinhibitorsinterviewisth2022jointkeynotekidneylandscapelargelateldlleukemialifelipidliraglutidelonglowerloweringlunglymphocyticlymphomamanagementmanagingmelanomametastaticmultiplemyeloidmyelomanovelnoveltiesobesityoptimaloptionsoutcomesoverallpacingpatientpatientspembrolizumabpeoplephasepluspositivepostpracticepressurepreventionprogressionprostatepulmonaryquestionsrandomizedrccrealreceptorrecurrencerefractoryrelapsedrenalresultsriskrolesabcs2024screeningsemaglutidesessionsglt2showsststandardstatestrategiesstudysurgerysurvivalsymposiumsyndromessystemictargetedtermtherapeutictherapiestherapytreattreatmenttrialtrialstripleupdateupdatesusevaccineversuswcclworldwvcdc